Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
The present invention recognizes that medical devices, such as but not limited to contact lenses, can be made having a coating made at least in part using printing technologies to provide drug storage and drug release structures. The coating preferably includes at least one drug reservoir layer and a least one barrier layer, and can include structures, such as but not limited to capillary structures that alone or in combination modulate the release of the drug from the coating. One aspect of the present invention is a medical device that incorporates a drug in at least one coating.
1. A packaged medical device, comprising:
a) at least one drug delivery contact lens, comprising:
1) at least one coating provided on at least one surface of said drug delivery contact lens; and
2) at least one drug;
b) at least one packaging solution, comprising:
1) said at least one drug;
c) at least one packaging, comprising:
1) said at least one drug delivery contact lens; and
2) said at least one packaging solution;
wherein said at least one coating comprises said at least one drug; and
further wherein said at least one coating is made in whole or in part by at least one additive printing.
2. The packaged medical device of claim 1 ;
wherein said at least one drug is provided in a pharmaceutically effective amount.
3. The packaged medical device of claim 1 ;
wherein said at least one drug comprises an antibiotic, an intraocular pressure reducing agent, a comfort enhancing agent, an anti-inflammatory agent, a penetration enhancer, a macular degeneration agent, or a combination thereof.
4. The packaged medical device of claim 1 ;
wherein said at least one drug comprises gentamicin, tobramycin, erythromycin, polytrim, cirproflizacin, viamox, xymar, or a combination thereof.
5. The packaged medical device of claim 1 ;
wherein said at least one drug comprises timolol, alphagan, axopt, cosopt, lumigan, travatan, xalatan, combigan, timolol hemihydrate, betaxolol, levobunolol, metipranolol, apraclonidine, Brimonidine tartate, Brinzolamide, methazolamide, dorzolamide, acetazolamide, carbachol, travoprost, latanoprostene bunod, tafluprost, netarsudil, or a combination thereof.
6. The packaged medical device of claim 1 ;
wherein said at least one drug comprises sodium hyaluronate, hyaluronic acid, cyclosporine, polyethylene glycol 400, hypromellose, polyvinyl alcohol, carboxymethylcellulose, dextran 70, hydroxypropyl methylcellulose, anhydrous liquid lanolin, mineral oil, white petroleum, mannitol, thiomersal, carbomer, cetrimide, glycerin, polysorbate80, povidine, or a combination thereof.
7. The packaged medical device of claim 1 ;
wherein said at least one drug comprises, perdforte, lotemax, fluromethlone, nevanac, acular, xibrom, or a combination thereof.
8. The packaged medical device of claim 1 ;
wherein said at least one drug comprises, Flurbiprofen, Acetazolamide, ethylenediaminetetraacetic acid, palmitoyl carnitine, sodium caprate, sodium dodecylsulphate, sodium deoxycholate, poly oxyethylene-g-lauryl ether, 1-α-lysophosphatidylocholine, deoxycholate, taurodeoxycholate, glycocholate, benzalkonium chloride, or a combination thereof.
9. The packaged medical device of claim 1 ;
wherein said at least one drug comprises EYLEA® (aflibercept) .
10. The packaged medical device of claim 1 ;
wherein said at least one drug comprises dexamethasone, pilocarpine nitrate, tropicamide, methyl prednisolone, flurbiprofen, penicillin ciprofloxacin, sulphacetaminde sodium, indomethacin, hydrocortisone, indomethacin, ciprofloxacin hydrochloride, insulin, indomethacin, ketorolac tromethamine, or a combination thereof.
11. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises an antibiotic, an intraocular pressure reducing agent, a comfort enhancing agent, an anti-inflammatory agent, a penetration enhancer, a macular degeneration agent, or a combination thereof.
12. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises gentamicin, tobramycin, erythromycin, polytrim, cirproflizacin, viamox, xymar, or a combination thereof.
13. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises timolol, alphagan, axopt, cosopt, lumigan, travatan, xalatan, combigan, timolol hemihydrate, betaxolol, levobunolol, metipranolol, apraclonidine, Brimonidine tartate, Brinzolamide, methazolamide, dorzolamide, acetazolamide, carbachol, travoprost, latanoprostene bunod, tafluprost, netarsudil, or a combination thereof.
14. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises sodium hyaluronate, hyaluronic acid, cyclosporine, polyethylene glycol 400, hypromellose, polyvinyl alcohol, carboxymethylcellulose, dextran 70, hydroxypropyl methylcellulose, anhydrous liquid lanolin, mineral oil, white petroleum, mannitol, thiomersal, carbomer, cetrimide, glycerin, polysorbate80, povidine, or a combination thereof.
15. The packaged medical device of claim 1 ;
wherein said at least one packaging comprises at least one blister pack.
16. The packaged medical device of claim 1 ;
wherein said at least one packaging comprises at least one vial.
17. The medical device of claim 1 ,
wherein said at least one additive printing comprises ink jet printing.
18. The medical device of claim 1 ,
wherein said at least one additive printing comprises digital printing, 3D printing, digital 3D printing, or a combination thereof.
19. The packaged medical device of claim 1 ;
wherein said at least one additive printing comprises additive 3D printing.
20. The packaged medical device of claim 1 ;
wherein said at least one coating comprises one or more layers.
21. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises, perdforte, lotemax, fluromethlone, nevanac, acular, xibrom, or a combination thereof.
22. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises, Flurbiprofen, Acetazolamide, ethylenediaminetetraacetic acid, palmitoyl carnitine, sodium caprate, sodium dodecylsulphate, sodium deoxycholate, poly oxyethylene-g-lauryl ether, 1-α-lysophosphatidylocholine, deoxycholate, taurodeoxycholate, glycocholate, benzalkonium chloride, or a combination thereof.
23. The packaged medical device of claim 1 ;
wherein said at least one drug comprises atropine.
24. The packaged medical device of claim 1 ;
wherein said at least one packaging solution further comprises atropine.